{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T22:40:07Z","timestamp":1719528007761},"reference-count":20,"publisher":"Kurume Medical Journal","issue":"1.2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2739\/kurumemedj.ms6406","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T22:19:32Z","timestamp":1508451572000},"page":"29-33","source":"Crossref","is-referenced-by-count":3,"title":["Anaplastic Thyroid Carcinoma Treated with Lenvatinib"],"prefix":"10.2739","volume":"64","author":[{"given":"JUN-ICHI","family":"OHKUBO","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AZUSA","family":"TAKAHASHI","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHOJI","family":"IKEZAKI","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FUMIKO","family":"TAKENAGA","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUFU","family":"OHKUBO","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIDEAKI","family":"SUZUKI","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1445","reference":[{"key":"1","unstructured":"1. Koussis H, Maruzzo M, Scola A, Ide EC, Fassina A et al. A case of anaplastic thyroid cancer with long-term survival. Anticancer Res. 2010; 30:1273-1278."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smallridge RC and Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010; 22:486-497.","DOI":"10.1016\/j.clon.2010.03.013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kim TY, Kim KW, Jung TS, Kim JM, Kim SW et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck. 2007; 29:765-772.","DOI":"10.1002\/hed.20578"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kebebew E, Greenspan FS, Clark OH, Woeber KA, and McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103:1330-1335.","DOI":"10.1002\/cncr.20936"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A et al. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 2012; 36:1247-1254.","DOI":"10.1007\/s00268-012-1437-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012; 22:1104-1139.","DOI":"10.1089\/thy.2012.0302"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Scott LJ. Lenvatinib: first global approval. Drugs. 2015; 75:553-560.","DOI":"10.1007\/s40265-015-0383-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014; 2014:638747.","DOI":"10.1155\/2014\/638747"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372:621-630.","DOI":"10.1056\/NEJMoa1406470"},{"key":"10","unstructured":"10. Crile G Jr and Wilson DH. Transformation of a low grade papillary carcinoma of the thyroid to an anaplastic carcinoma after treatment with radioiodine. Surg Gynecol Obstet. 1959; 108:357-360."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kaushal S, Sharma MC, Mathur SR, Rastogi S, Bal CS et al. Anaplastic transformation of metastatic papillary thyroid carcinoma at shoulder mimicking soft tissue sarcoma. Indian J Pathol Microbiol. 2011; 54:796-799.","DOI":"10.4103\/0377-4929.91512"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck. 1996; 18:36-41.","DOI":"10.1002\/(SICI)1097-0347(199601\/02)18:1<36::AID-HED5>3.0.CO;2-#"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kihara M, Miyauchi A, Yamauchi A, and Yokomise H. Prognostic factors of anaplastic thyroid carcinoma. Surg Today. 2004; 34:394-398.","DOI":"10.1007\/s00595-003-2737-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ito Y, Higashiyama T, Hirokawa M, Fukushima M, Inoue H et al. Prognosis of patients with papillary carcinoma showing anaplastic transformation in regional lymph nodes that were curatively resected. Endocr J. 2008; 55:985-989.","DOI":"10.1507\/endocrj.K08E-148"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shinohara S, Kikuchi M, Naito Y, Fujiwara K, Hori S et al. Successful treatment of locally advanced anaplastic thyroid carcinoma by chemotherapy and hyperfractionated radiotherapy. Auris Nasus Larynx. 2009; 36:729-732.","DOI":"10.1016\/j.anl.2009.02.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Seto A, Sugitani I, Toda K, Kawabata K, Takahashi S et al. Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases. Surg Today. 2015; 45:221-226.","DOI":"10.1007\/s00595-013-0751-x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hsu KT, Yu XM, Audhya AW, Jaume JC, Lloyd RV et al. Novel approaches in anaplastic thyroid cancer therapy. Oncologist. 2014; 19:1148-1155.","DOI":"10.1634\/theoncologist.2014-0182"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Romitti M, Ceolin L, Siqueira DR, Ferreira CV, Wajner SM et al. Signaling pathways in follicular cell-derived thyroid carcinomas (review). Int J Oncol. 2013; 42:19-28.","DOI":"10.3892\/ijo.2012.1681"},{"key":"19","unstructured":"19. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014; 12:1671-1680."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013; 23:600-604.","DOI":"10.1089\/thy.2012.0103"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/64\/1.2\/64_MS6406\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T22:05:49Z","timestamp":1719525949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/64\/1.2\/64_MS6406\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":20,"journal-issue":{"issue":"1.2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms6406","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"value":"0023-5679","type":"print"},{"value":"1881-2090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}